The relative merits of allogeneic hematopoietic stem cell transplantation (allo-HSCT) and imatinib for chronic myelogenous leukemia in the accelerated phase (AP-CML) have not previously been evaluated. This cohort study was designed to compare the outcomes of imatinib (n = 87) versus allo-HSCT (n = 45) for AP-CML. A multivariate analysis of the total population revealed that a CML duration > 12 months, hemoglobin < 100 g/L, and peripheral blood blasts > 5% were independent adverse prognostic factors for both overall survival (OS) and progression-free survival (PFS). Both treatments resulted in similar survival in low-risk (no factor) patients, with 6-year event-free survival (EFS), OS, and PFS rates of more than 80.0%. Intermediate...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. W...
Although imatinib has become standard first-line therapy in chronic myelogenous leukemia (CML), allo...
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chroni...
Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...
Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...
The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transpla...
The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transpla...
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative appr...
To determine the impact of imatinib therapy prior to allogeneic stem-cell transplantation in advance...
Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as primary treatme...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. W...
Although imatinib has become standard first-line therapy in chronic myelogenous leukemia (CML), allo...
Imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chroni...
Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...
Although the drug imatinib has been accepted as the treatment of choice for chronic myelogenous leuk...
The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transpla...
The introduction of imatinib mesylate has changed attitudes towards hematopoietic stem cell transpla...
Background/Aim. Introducing tyrosine kinase inhibitors (TKIs) has essentially changed curative appr...
To determine the impact of imatinib therapy prior to allogeneic stem-cell transplantation in advance...
Early allogeneic hematopoietic stem cell transplantation (HSCT) has been proposed as primary treatme...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...
Tyrosine kinase inhibitors represent today's treatment of choice in chronic myeloid leukemia (CML). ...